The autoimmune testing landscape is shifting from single-analyte assays toward multiplex, high-sensitivity platforms capable of detecting multiple biomarkers from a single sample. Laboratories are ...

Record full-year total revenue and AVISE® CTD average selling price New biomarkers and sales force expansion drove over 11% full-year test volume ...

Exagen Inc. has reached a major milestone by completing its 1,000,000th AVISE CTD test, a diagnostic tool for autoimmune and connective tissue diseases. This achievement highlights the company’s ...

CARLSBAD, Calif., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (XGN), a leading provider of autoimmune testing, today announced the completion of its 1,000,000 th AVISE CTD test, marking a ...

Chronic fatigue or joint pain? It could be autoimmune. Learn how to get tested and what new biologic drugs could mean for treatment.

Autoimmune diseases are on the rise. It’s not just a hunch—autoimmune diseases are rising sharply, and the numbers are too significant to ignore. These chronic conditions, where the immune system ...

CARLSBAD, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Exagen Inc., a leading provider of autoimmune testing, today announced the validation and regulatory submission for approval of new Systemic Lupus ...

CARLSBAD, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (XGN), a leading provider of innovative autoimmune testing, is pleased to announce the appointment of Dr. Michael Mahler as Chief ...

Autoimmune rheumatic diseases (ARDs) represent a diverse group of conditions in which the immune system mistakenly targets the body’s own tissues, often affecting the musculoskeletal system and ...

The MarketWatch News Department was not involved in the creation of this content. CARLSBAD, Calif., Jan. 11, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune ...

CARLSBAD, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced that it has commenced an underwritten public offering ...

The global autoimmune disease testing market is witnessing steady expansion as healthcare systems intensify focus on early diagnosis and chronic disease management. Valued at USD 4.94 billion in 2025, ...